Injections of brain protein reverse memory loss in mice

This protein is crucial for making memories, and it’s disrupted in Alzheimer’s.

A brain protein linked to memory formation could be the foundation of new Alzheimer’s treatments that don’t just slow disease progression but could actually reverse memory loss. 

The treatment hasn’t yet been tried in people, so we don’t know if it’ll work in real Alzheimer’s cases, or if it would improve life expectancy for people with the disease.

The challenge is huge: There’s a lot we don’t understand about Alzheimer’s disease, but we do know that patient’s brains tend to accumulate toxic tau and amyloid-beta proteins, so most research has focused on those targets.

That approach has led to new drugs that can slow the progression of Alzheimer’s to a small degree, but we’ve yet to find anything that can reverse the damage the disease does to the brain.

“It was very surprising how strong the relationship was.”

Tara Tracy

The big idea: Synapses — the connections between brain neurons — need a protein called “KIBRA” in order to form memories, and there’s a link between certain variants of the KIBRA gene and developing Alzheimer’s.

This inspired scientists at the Buck Institute for Research on Aging to dig deeper into the protein to see whether it could lead to new Alzheimer’s treatments.

What’s new? For their study, the Buck team measured KIBRA levels in the cerebrospinal fluid (CSF) of 25 older adults (10 with Alzheimer’s and 15 who were clinically healthy), as well as in frozen brain tissue samples from people who died with and without Alzheimer’s.

They discovered a correlation between decreased KIBRA levels in the brain but elevated levels in CSF and how severe patients’ dementia was.

“We also found this amazing correlation between increased tau levels and increased KIBRA levels in the cerebrospinal fluid,” said senior author Tara Tracy. “It was very surprising how strong the relationship was, which really points to the role of KIBRA being affected by tau in the brain.”

A diagram showing the differences in tau, KIBRA, and cognitive decline in people with and without Alzheimer's disease
Kauwe et al. (2024)

They aren’t sure why having more tau in the brain seems to lead to more KIBRA in CSF — in their study, they suggest that neurons with dysfunctional synapses might somehow expel the protein, causing it to accumulate in CSF, but confirming that would require more research.

Still, simply knowing about the connection could be useful — measuring KIBRA levels in a person’s CSF might one day help doctors diagnose Alzheimer’s or track its progression, for example.

A new treatment? The scientists injected a lab-made version of the KIBRA protein into the brains of mouse models of Alzheimer’s — and it reversed their memory loss.

“Interestingly, KIBRA restored synaptic function and memory in mice, despite not fixing the problem of toxic tau protein accumulation,” said co-first author Kristeen Pareja-Navarro.

In other words, the protein reversed a symptom (memory loss) even without apparently affecting the underlying disease.

Looking ahead: This is still early research, and results in mice often don’t translate to people — especially in Alzheimer’s research. Still, the Buck team is hopeful its study will prove to be a stepping stone to much needed new Alzheimer’s treatments. 

“Reducing toxic proteins is of course important, but repairing synapses and improving their function is another critical factor that could help,” said Tracy. “That’s how I see this making the biggest impact in the future.”

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

What hybrid mouse/rat brains are showing us about the mind
Modified mice with hybrid brains that include rat neurons could one day lead to new breakthroughs in neuroscience.
How sensory gamma rhythm stimulation clears amyloid in Alzheimer’s mice
Study finds stimulating a brain rhythm with light and sound increases peptide release from interneurons, possibly slowing Alzheimer’s progression.
Brain implant for “artificial vision” is still working after 2 years
A new type of brain implant technology has given a man with total blindness a kind of “artificial vision.”
Why a neurodivergent team will be a golden asset in the AI workplace
Since AI is chained to linear reasoning, workplaces that embrace it will do well to have neurodivergent colleagues who reason more creatively.
In a future with brain-computer interfaces like Elon Musk’s Neuralink, we may need to rethink freedom of thought
In a future with more “mind reading,” thanks to computer-brain interfaces, we may need to rethink freedom of thought.
Up Next
a collage of a 3D bioprinter and brain tissue
Subscribe to Freethink for more great stories